Samsung Biologics posted record Q2 results with revenue of 1.3209 trillion won and operating profit of 586.4 billion won, the company announced on the 23rd. Revenue increased 30.2% and operating profit rose 22.9% compared to the same period last year. The performance was driven by full operation of Plants 1-4 in Songdo and favorable exchange rates. The company's cumulative contract manufacturing organization (CMO) orders reached $24.3 billion (approximately 36 trillion won) as of the end of June, up from $16.3 billion at the end of 2024. Samsung Biologics operates in the biopharmaceutical CMO sector, producing drugs under contract for global pharmaceutical companies.
Samsung Biologics Records Highest Q2 Operating Profit
Samsung Biologics achieved revenue of 1.3209 trillion won and operating profit of 586.4 billion won in Q2. The figures represent increases of 30.2% and 22.9% respectively compared to the same quarter last year. The revenue marked the highest quarterly figure on record, while operating profit was the highest ever recorded for a second quarter. The results aligned with market consensus estimates. According to investment information platform Epic AI, securities firms estimated Q2 revenue and operating profit at 1.3273 trillion won and 594 billion won respectively.
First Half 2025 Results Reach Record Highs
For the first half of the year, Samsung Biologics reported revenue of 2.578 trillion won and operating profit of 1.1672 trillion won. Both figures increased 28.0% and 28.6% respectively compared to the same period last year, setting new records for a half-year period. Samsung Biologics stated that Plants 1-4 in Songdo are in full operation and exchange rates remain favorable, contributing to steady performance growth. The company noted that Plant 5, recently completed, has not yet reached full operation, and results from the Rockville, Maryland plant in the United States are not yet reflected in the figures.
CMO Orders Surge to $24.3 Billion
Samsung Biologics' cumulative CMO orders reached $24.3 billion (approximately 36 trillion won) as of the end of June. This represents an increase from $16.3 billion at the end of 2024 and $21.2 billion at the end of last year. Ordered volumes are delivered to customers after a minimum production period of three months.
Samsung Biologics Expands Global Operations and Acquires Polypeptide Group
Samsung Biologics is expanding its global sales network and diversifying its product portfolio. In addition to existing sales offices in the United States and Japan, the company plans to open a Netherlands office in Q3. On the 20th, Samsung Biologics announced plans to acquire Swiss peptide drug contract development and manufacturing organization (CDMO) company Polypeptide Group for approximately 2.7 trillion won.
FAQ
What were Samsung Biologics' Q2 2025 financial results?
Samsung Biologics reported Q2 revenue of 1.3209 trillion won and operating profit of 586.4 billion won, representing year-over-year increases of 30.2% and 22.9% respectively. The revenue was the highest quarterly figure on record, and operating profit was the highest ever for a second quarter.
How much are Samsung Biologics' cumulative CMO orders worth?
As of the end of June, Samsung Biologics' cumulative contract manufacturing organization orders totaled $24.3 billion, equivalent to approximately 36 trillion won. This increased from $16.3 billion at the end of 2024 and $21.2 billion at the end of last year.
What acquisition did Samsung Biologics announce?
On the 20th, Samsung Biologics announced plans to acquire Polypeptide Group, a Swiss peptide drug contract development and manufacturing organization company, for approximately 2.7 trillion won.
